AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Conneqt Health Limited (ASX:CQT) has revised the schedule for its Share Purchase Plan (SPP), extending the offer closing date to July 31, 2026. This extension provides eligible shareholders in Australia and New Zealand more time to participate in the capital raising initiative. The updated plan allows for the issuance of up to 22,727,273 ordinary fully paid shares at AUD 0.02200 each, with proceeds allocated to product inventory, new product development, marketing efforts, and working capital needs.
Key Points
- Conneqt Health Limited (CQT) is conducting a Share Purchase Plan for eligible investors.
- The SPP timetable has been updated, extending the offer closing date to July 31, 2026, from the previously announced date.
- Up to 22,727,273 ordinary fully paid shares will be issued at AUD 0.02200 per share, with investment options ranging from AUD 1,000 to AUD 30,000 per application.
- Funds raised will support product inventory, intellectual property and new product development, marketing and sales initiatives, and working capital.
- The SPP is exclusively open to eligible security holders in Australia and New Zealand, with results expected by August 7, 2026.
- Stralis Capital Partners is appointed as lead manager, receiving a 1% advisory fee on gross proceeds from the SPP.
Share Purchase Plan Details and Eligibility Criteria
Conneqt Health Limited’s Share Purchase Plan offers eligible shareholders in Australia and New Zealand an opportunity to invest directly in the company’s growth. Shares will be issued at a fixed price of AUD 0.02200 per security. The offer is geographically limited to these two countries, reflecting regulatory compliance and the company’s strategic market focus.
Eligible investors can apply for shares in set parcels ranging from AUD 1,000 up to a maximum of AUD 30,000 per application. This tiered structure facilitates broad participation while controlling individual exposure levels.
Extended Offer Period Enhances Investment Window
The original SPP timetable announced on June 19, 2026, has been amended to extend the offer closing date to July 31, 2026. Applications opened on June 30, 2026, and this extension grants shareholders additional time to evaluate the offer and submit their applications.
The record date for eligibility was June 18, 2026. Following the extended closing date, results and share issuance will be announced on August 7, 2026. This adjustment accommodates operational and market factors, providing clarity and predictability to participants.
Allocation of Capital Raised Through the SPP
Proceeds from the SPP will be directed toward enhancing product inventory to meet anticipated sales growth, investing in intellectual property and new product development, and funding marketing and sales initiatives aimed at enterprise expansion. Additionally, working capital will be allocated to support ongoing operational requirements, ensuring the company maintains liquidity to execute its strategic plans.
Share Issuance Limits and Pricing
The plan allows for the issuance of up to 22,727,273 ordinary fully paid shares at AUD 0.02200 each. While the total capital raise amount has not been disclosed, the maximum issuance reflects full subscription at the highest permitted investment level.
New shares will rank equally with existing ordinary shares from the issue date, ensuring equal economic and voting rights. The SPP complies with ASX Listing Rule 7.2 exception 5, requiring no waivers or special approvals.
Unconditional Proceeding Without External Approvals
The company confirmed that the SPP will proceed unconditionally without requiring shareholder or regulatory approvals. There are no minimum or maximum subscription conditions, and no scale-back provisions apply, guaranteeing full acceptance of all valid applications from eligible investors.
Stralis Capital Partners Engaged as Lead Manager and Advisor
Stralis Capital Partners has been appointed lead manager and advisor for the SPP, receiving a 1% advisory fee based on gross proceeds. No handling fees or commissions will be paid to brokers for application processing, and no other significant fees are expected, ensuring maximum capital is directed toward company initiatives.
Conneqt Health’s Position in the Healthcare Sector
Operating in the healthcare sector, Conneqt Health’s investment in product development, inventory, and marketing reflects the capital-intensive nature of the industry. The company’s balanced approach to growth—combining innovation with sales and marketing efforts—positions it to strengthen market share amid evolving customer demands and regulatory environments.
Investor Eligibility and Geographic Restrictions
The SPP is exclusively available to security holders in Australia and New Zealand, excluding investors from all other jurisdictions due to regulatory and strategic considerations. Detailed offer documentation is accessible via the company’s investor relations website at https://conneqthealth.com/investors/.
This geographic focus aligns with Conneqt Health’s core markets and simplifies compliance with local securities laws.
Important Dates and Result Announcement
The SPP opened on June 30, 2026, with the extended closing date of July 31, 2026, providing approximately one month for investor participation. Results and share issuance are scheduled for August 7, 2026, enabling prompt processing and transparency for participants.
Eligible investors must submit applications by July 31, 2026, to participate. Comprehensive information is available through the company’s official channels.
